Management of cancer-associated thrombosis in people with advanced disease

Simon Noble, Miriam J Johnson

The management of venous thromboembolism in the cancer population is clearly established. Low molecular weight heparin has a greater efficacy than warfarin in the treatment of cancer-associated thrombosis and is recommended as the preferred therapy. However, the evidence informing these recommendations excluded patients with poor prognosis or performance status, thrombocytopenia, bleeding or brain metastases. Furthermore, there is limited data on the management of venous thromboembolism resistant to anticoagulation, a phenomenon frequently encountered in the advanced cancer population. This paper will review the management of cancer-associated thrombosis with a particular focus on challenging clinical situations faced by palliative care teams looking after patients with advanced disease.

INTRODUCTION

The association between cancer and venous thromboembolism (VTE) is widely recognised. People with cancer have a higher risk of developing deep vein thrombosis (DVT) and pulmonary embolus (PE) than those without cancer due to secretion of cancer related procoagulants, which increase with advancing disease and therapeutic interventions including surgery and chemotherapy.1–5 Cancer-associated thrombosis has a significant negative impact on survival.6 7

Up to 15% of cancer patients are estimated to develop clinically apparent VTE, although this is likely to be an underestimate of the problem.1 4 The prevalence of both symptomatic and undiagnosed VTE in advanced disease is thought to be as high as 52%, in keeping with postmortem studies8–10 and although the clinical relevance of unsuspected or incidental VTE (typically discovered on staging CT scans) is not fully understood, recent work suggests that cancer patients diagnosed with and treated for incidental PE have similar recurrent VTE and survival to those who had symptomatic PE.11 12

Most participants in the clinical studies that inform the evidence base for the management of cancer-associated VTE were relatively fit ambulant patients (Eastern Cooperative Oncology Group (ECOG) 0-2). Therefore applying treatment guidelines to those with poorer performance status, such as the majority of those cared for in palliative care settings can be difficult. This article reviews the current evidence for managing secondary prevention of cancer-associated thrombosis. In addition it will focus on challenging clinical problems where there is no current evidence to inform practice.

SCOPE OF THE PROBLEM

Management of patients with VTE and advanced cancer is challenging for several reasons. First, there is an increased risk of bleeding and recurrent VTE with anticoagulation, particularly with vitamin K antagonists (VKA) compared with non-cancer patients.15–24 As the cancer progresses, so too does the risk of VTE and bleeding.25 Several factors contribute to this: decreased patient mobility, compression of venous return by tumour masses and the presence of highly vascular ulcerating lesions. Furthermore, worsening disseminated intravascular coagulation will result in increasing activation of the coagulation cascade and a tendency to bleed. Thrombocytopenia, due to marrow invasion or as a complication of treatment, may further increase the risk of bleeding.

Second, the advanced cancer population is difficult to define since the term ‘advanced cancer patient’ refers to a highly heterogeneous group of differing histology, performance status, metastatic burden, mobility and prognosis. These physical variables will affect patients’ thrombogenicity and bleeding risks. The direction of patient care will often change to a focus on quality of life rather than quantity. It is vitally important to involve patients in their own management plans, particularly at this stage of their lives. Their wishes will be influenced by their current goals and fears in addition to the symptom burden of their disease. For some, a relatively minor insult such as a small PE or minor DVT may have a disproportionately large impact on quality of life while others may consider the potential consequences of treating their VTE to exceed the symptoms.

TREATMENT OF SYMPTOMATIC VTE

To treat or not to treat?

Studies informing the management of cancer-associated thrombosis have all been conducted under the assumption that the patient should receive anticoagulation, with the research question focusing on the choice of anticoagulant to be used. Even in the cancer population, where anticoagulation carries additional hazards, for the majority of patients the benefits of treating symptomatic VTE far outweigh the risks. However, in the palliative care setting the clinician may encounter situations where treating the VTE could be inappropriate or a patient already on anticoagulation should have it discontinued.

There is no evidence to guide these decision-making processes and so we would suggest a pragmatic approach. As discussed before, the progression of malignant disease brings with it increasing bleeding complications and the
potential hazards of anticoagulation should not be underestimated. Long-term anticoagulation in the absence of objective radiological confirmation seems counter intuitive and if investigation of a suspected thrombotic event is considered inappropriate, then arguably so is anticoagulation. Similarly, it would be inappropriate to investigate a suspected thrombus if there were no intention to treat the suspected VTE.

If a patient is near the end of life, with anticipated deterioration any symptoms attributable to VTE could be managed with appropriate end of life medications. For patients who are not imminently dying, anticoagulation may be useful in relieving symptoms attributable to VTE.

Anticoagulation strategies
The anticoagulants that are commonly used in symptomatic VTE are illustrated in figure 1, which identifies their sites of action within the coagulation cascade. The treatment for VTE in the general non-cancer population consists of 3–6 months anticoagulation with warfarin after initial anticoagulation with weight-adjusted low molecular weight heparin (LMWH). The use of VKAs such as warfarin in the cancer population, however, is associated with bleeding rates as high as 21.6% and the initial warfarin loading in advanced cancer patients has reported international normalised ratios (INRs) greater than 4.5 in over 60% of patients and greater than 8 in 30%. Maintaining a stable INR is similarly difficult due to poor nutritional status, liver metastases, variable oral intake/drug absorption and drug-drug interactions.

In addition to an increased risk of bleeding, cancer patients are more likely to develop further thrombotic events on VKAs than non-cancer patients. Studies have shown up 27% of cancer patients receiving therapeutic VKA will develop secondary VTE. Although several trials have studied long-term therapy for VTE with oral anticoagulant versus weight-adjusted LMWH, only three have looked at patients with cancer. Meyer and colleagues randomised patients with cancer and VTE to 3 months of treatment with either LMWH enoxaparin (1 mg/kg) or warfarin. The composite outcome of major bleeding and recurrent VTE was observed in 15 out of 71 (21.1%) patients receiving warfarin, compared with 7 of the 67 (10.5%) receiving LMWH (p=0.09). The long-term innohep treatment evaluation trial randomised 200 patients with acute VTE and cancer to receive either unfractionated heparin (UFH) followed by warfarin for 84 days at a targeted INR of 2.5 or the LMWH tinzaparin (175 IU/kg) for 85 days. The rate of recurrent VTE at 3 months was 6% in the LMWH group compared with 10% in the warfarin group and at 1 year 7% and 16% respectively (p=0.044).

The CLOT trial, was a large multicentre study comparing treatment with dalteparin (200 IU/kg for 1 month, then 150 IU/kg for 5 months) with oral anticoagulant therapy in patients with active cancer presenting with acute VTE. Three hundred and thirty-eight patients were enrolled into

Figure 1  Simplified coagulation cascade illustrating site of action of anticoagulants
each arm and were well matched for gender, age, outpatient treatment and performance status. Twenty-seven patients in the LMWH group experienced recurrent VTE compared with 53 in the oral anticoagulant group. Patients receiving long-term LMWH treatment had a significantly lower cumulative risk of recurrent VTE at 6 months than those who received long-term oral anticoagulant therapy (8.8% vs 17.4%; 52% risk reduction, \( p=0.0017 \)). Major bleeding was seen in 19/335 (5.6%) patients receiving LMWH compared with 12/336 (3.6%) in the oral anticoagulant group which was statistically non-significant (\( p=0.27 \)). Corresponding data for any bleeding were 13.6% and 18.5%, respectively (\( p=0.09 \)). In view of these data, LMWH has been recommended for long-term anticoagulation in cancer patients in clinical guidelines.\(^{27-30}\)

When considering whether these studies are applicable to those with advanced cancer one must consider the patient exclusion criteria. These are summarised in table 1. All studies excluded those with estimated life expectancy <3 months, brain metastases, thrombocytopenia less than 75,000/mm\(^3\) and active bleeding. Poor performance status was also an exclusion criterion with one study excluding those of ECOG scores 3–4.\(^{22}\) However, over 40% of patients in each study were classed as having metastatic disease or were no longer receiving active treatments for their cancer suggesting the evidence to be applicable to the majority of patients with metastatic disease. Furthermore, a systematic review and meta-analysis conducted by an Association for Palliative Medicine of Great Britain and Ireland task group recommended LMWH as the anticoagulant of choice in patients with advanced malignancy.\(^{31}\) There is emerging published literature reporting experience of long-term LMWH use in patients with an average median survival of approximately 3 months and included patients with brain metastases; patients who would have been excluded from the above studies.\(^{32,33}\)

Although LMWH administration requires a daily subcutaneous injection, findings from qualitative research suggest that patients find it an acceptable intervention.\(^{34}\) However, it must be noted that most patients participating in the interview study had only been on LMWH for a month, we do not know how they might feel after several months. In addition, these patients had prior poor experience of warfarin since LMWH was not standard practice at the time of the study. Many patients found it preferable to use warfarin since maintenance of a stable INR was reported to require frequent monitoring and these repeated blood tests had a negative impact on quality of life. The health economic implications of using LMWH in advanced cancer patients need to be considered and some services have suggested the cost of LMWH to be prohibitive.\(^{35}\)

The majority of patients or carers can be taught to administer the drug, negating the potential additional cost of community nursing involvement.\(^{32}\)

**Recurrent VTE despite use of weight-adjusted LMWH**

Occasionally, a cancer patient will have VTE resistant to LMWH because of subtherapeutic levels of the drug or tumour driven direct thrombin activation which will bypass the factor Xa, thus rendering LMWH ineffective. Recurrence of VTE despite therapeutic anticoagulation with LMWH confers a poor prognosis and published data on its management is limited. The focus of management should be on reducing the symptomatic burden without introducing new symptoms from changing therapeutic approaches or complications of therapies.

Possible approaches include increasing the dose of LMWH, if sub-therapeutic, changing to twice-daily injections to minimise trough levels, or switching to intravenous or subcutaneous UFH, where direct thrombin activation is suspected or rapid reversal in a highly thrombotic state prior to surgery is needed.

**Initial management**

In the CLOT study, the LMWH dose was reduced to 75% after 1 month.\(^{21}\) Therefore the initial management of recurrent VTE should be to ensure that, if the dose has been previously reduced, full weight adjusted dose LMWH is reinstated. If this does not work, there is little in the published literature to guide the clinician. A case series of 47 cancer patients with recurrent VTE despite full weight-adjusted LMWH describes resolution of VTE attributable symptoms within following an empirical increase in LMWH dose by 25%.\(^{36}\) However, there is insufficient evidence to recommend this routinely. The utility of anti-Xa level monitoring in this situation is unclear. To date there are no studies supporting the use of anti-Xa levels to guide LMWH dosing in the cancer patient and published data is limited to a single case report.\(^{37}\) Further management requires liaison with haematology colleagues for guidance and it is likely that treatment plans will be developed on an individual patient basis. The role of anti-Xa levels in the dosing of LMWH in cancer-associated thrombosis needs further research.

**Direct thrombin activation**

Assuming LMWH levels are therapeutic, it is possible that direct thrombin activation is the underlying driver of recurrent VTE and a change to UFH may be warranted. The new oral direct thrombin inhibitors may have a future role to play in the

---

**Table 1 Randomised control trials comparing oral vitamin K antagonists with low molecular weight heparin**

<table>
<thead>
<tr>
<th>Study</th>
<th>Bleeding, Warfarin:LMWH</th>
<th>Advanced cancer indices</th>
<th>LMWH regime</th>
<th>At 3 months: 10/100(10%): 6/100 (6%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Major: 12/75 (16%): 5/71 (7%)</td>
<td>Metastatic disease: 52%</td>
<td>Excluded if &lt;3 month prognosis</td>
<td>Major: 12/335 (4%); 19/335 (6%)</td>
</tr>
<tr>
<td>Meyer 22</td>
<td>Performance status 3, 4 and Weight&lt;40 kg excluded</td>
<td>Metastatic disease 67%</td>
<td>Enoxaparin (1.5 mg/kg)</td>
<td>Excluded if &lt;3 months prognosis</td>
</tr>
<tr>
<td>Leo 21</td>
<td>Metastatic disease 67%</td>
<td>Dalteparin 200 IU/kg for 1 month then 150 IU for 5 months</td>
<td>Tinzaparin (175 IU/kg)</td>
<td>At 1 year: 16/100 (16%): 7/100 (7%)</td>
</tr>
<tr>
<td>Hull 19</td>
<td>Metastatic disease: warfarin 36%; LMWH 47%</td>
<td></td>
<td></td>
<td>At 3 months: 24/100 (24%): 27/100 (27%)</td>
</tr>
</tbody>
</table>

---

**Note**: Exclusions highlighted in bold.
management of this challenging patient group. However, it is unclear yet whether the theoretical benefit of direct thrombin inhibition will bring with it an increased risk of bleeding. The role of new oral anticoagulants including direct thrombin and factor Xa inhibitors is discussed later in this article.

**VTE in thrombocytopenia**

Thrombocytopenia increases the risk of bleeding in cancer patients and is elevated further by anticoagulation. LMWH has not been formally evaluated in patients with a platelet count lower than 75,000/mm² and thus guidelines do not recommend LMWH in this situation. However, in patients with symptomatic proximal DVT or PE, options may be limited and the risks of anticoagulation with LMWH must be weighed against the consequences of choosing not to anticoagulate. There is some clinical experience of LMWH anticoagulation in cancer patients with platelet counts above 50,000/mm² and from the authors experience, LMWH has been used in extreme cases when platelets were as low as 25,000/mm². Monreal et al have described the use of dose reduction in people with thrombocytopenia, using doses as low as 2500 IU dalteparin in those with thrombocytopenia <10,000/mm². Those with thrombocytopenia did not have a higher bleeding complication rate than those without.

**VTE in patients with bleeding**

There is no published evidence to guide the clinician in this particularly challenging situation and management should be tailored to the individual after full discussion of the risks of each treatment option. A sensible first step is to try and stop the bleeding if possible. If this is not possible, then nuisance bleeding such as mild epistaxis or haemoptysis should not, in our opinion, prevent anticoagulation in patients with symptomatic VTE in whom the risk of clinically significant recurrence is high. If the bleeding is from a visible, easily monitored source which is unlikely to be life threatening then full anticoagulation should commence (or be continued) with careful review. If the bleeding is due to mucosal involvement by tumour, such as bowel, duodenal, bladder or vaginal disease a more cautious approach of reduced or even prophylactic doses should be used and the patient monitored closely. The haemostatic properties of a palliative radiotherapy should be considered as it is well tolerated and embolisation in carefully selected patients may be considered. If the haemoglobin remains stable and bleeding does not worsen, the dose can be slowly titrated up. A twice-daily LMWH regime may smooth out peaks in anticoagulation level. If there is active bleeding of a more serious and potentially life threatening nature (intracranial, retroperitoneal or upper gastrointestinal bleeding), then anticoagulation is contraindicated.

**USE OF VENA CAVAL FILTERS**

There is no evidence that insertion of a vena caval filter improves outcome for cancer patients with VTE who are bleeding and published studies are too small for useful conclusions. The evidence in the advanced cancer population is even weaker and given inferior vena cava (IVC) filters do not reduce symptoms of VTE or improve survival, the use of these devices are limited in the palliative setting.

However, for patients with contraindications to anticoagulation, or who continue to embolise despite therapeutic anti-coagulation, clinicians may consider there to be few, if any, alternative options and carefully selected, individuals may gain net-benefit. It is important to note that filter insertion does not suppress the underlying hypercoagulable state, and may even aggravate it. In addition, there is a concern that fatal PE might still result from thrombus formation in the vena cava proximal to the filter.

**DURATION OF THERAPY**

The length of treatment with an anticoagulant for the secondary prevention of recurrent VTE has not been studied in cancer patients of any stage disease. However, based on the consensus that patients with ongoing or irreversible risk factors for VTE need an extended duration of anticoagulant therapy, a minimum of 3–6 months of treatment is prescribed. Beyond this period, ‘indefinite’ therapy is traditionally recommended in patients with metastatic disease because their risk of recurrent VTE is high. In a recent study in 62 patients with advanced, metastatic cancer and VTE, three of the seven patients who stopped LMWH after 6 months of treatment developed symptomatic, recurrent thrombosis. This has recently been recognised as a priority for research.

**FUTURE CONSIDERATIONS**

Therapeutic advances in cancer management have resulted in people living longer with metastatic disease. VTE will continue to be a challenge in people with advanced cancer because the evidence base is extrapolated from healthier populations using outcome measures which may be less applicable to patients of poor performance status and prognosis. Clinical research in this group has always been fraught with difficulty and robust studies within representative populations will require large-scale collaboration between research teams if sufficient numbers are to be recruited. Likewise, palliative care practice will only change if the evidence is applicable and the outcome measures are meaningful. A greater emphasis on patient reported outcome measures, the symptomatic burden of VTE and its therapies as well as over all quality of life assessments are needed. Finally, release of new oral anticoagulants including direct Xa inhibitors (rivaroxaban, apixaban) and direct thrombin inhibitors (dabigatran etexilate) are potentially exciting developments in the prevention and treatment of VTE in the palliative care setting. Both dabigatran etexilate and rivaroxaban have been evaluated in the treatment of DVT and PE showing non-inferiority to warfarin with respect to recurrent VTE and bleeding. However, the use of dabigatran and rivaroxaban has been cautioned in high-risk groups such as cancer patients until studies with representative numbers of cancer patients are available. Only 5% and 6.8% of patients, respectively, had cancer and non-inferiority of these agents in this setting, compared with the current gold standard (LMWH) that is yet to be demonstrated. However, until their evaluation in other medical populations has been concluded, their potential role in the advanced cancer population remains theoretical.

**Contributors** SN and MJJ both conceived the idea for the paper and co-authored the paper together.

**Competing interests** None.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**REFERENCES**


Management of cancer-associated thrombosis in people with advanced disease

Simon Noble and Miriam J Johnson

BMJ Support Palliat Care 2012 2: 163-167 originally published online
February 29, 2012
doi: 10.1136/bmjspcare-2011-000166

Updated information and services can be found at:
http://spcare.bmj.com/content/2/2/163

These include:

References
This article cites 49 articles, 4 of which you can access for free at:
http://spcare.bmj.com/content/2/2/163#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Editor's choice (24)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/